Skip to content

Doctors and patients are flying blind as medical marijuana use rises, research lags

July 25, 2019 / Arfinn Med MD /

Doctors and patients are flying blind as medical marijuana use rises, research lags

Marijuana’s role in the health care universe has grown exponentially over the past few years. Currently, 33 U.S. states have legalized the use of medical marijuana, and more and more states are considering making it legal for recreational purposes as well. As cannabis becomes more accessible, many people are turning to tetrahydrocannabinol (THC) and cannabidiol (CBD) products to treat health issues like rheumatic and musculoskeletal disease (the aches and pains of arthritis).

Unfortunately, because cannabis remains illegal and classified as a Schedule 1 drugunder federal law (defined as being of no medical use), there has been a troubling lack of scientific and medical research on the effectiveness of cannabis treatments. This dearth of evidence-based data has left many health care providers unable to counsel their patients on everything from whether a cannabis treatment could be effective for their condition, to what dosages are appropriate, to how cannabis might interact with their other medications or health conditions.

Read Full Article Here

Stories you may be interested in

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More →

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More →

After 50 Years, U.S. Opens The Door To More Cannabis Crops For Scientists

After more than 50 years, the federal government is lifting a roadblock to cannabis research that scientists and advocates say has hindered rigorous studies of the plant and possible drug development. Since 1968, U.S. researchers have been allowed to use cannabis from only one domestic source: a facility based at the University of Mississippi, through a…
Read More →

Data Migration and Mapping Functions

Medical software does not have a good reputation for user experience and intuitive design. It can seem like a full-time job just learning how to use these software solutions.  In fact, according to a study from Stanford Medicine, 74% of doctors responded that their EMR increased the number of hours they work every day and…
Read More →

$2.7 million awarded for medical marijuana research in Colorado

The state has awarded $2.7 million for research into how medical marijuana could replace opioids to ease chronic spinal pain — and how it might treat irritability in children and adolescents with autism. Read the full story here.
Read More →

REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals

Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More →

Leave a Comment

You must be logged in to post a comment.